PLK4 and cancer: An in vitro experimental study showed that a novel inhibitor of PLK4, CFI-400945, in combination with radiation, exhibited a synergistic anti-cancer effect in TNBC cell lines and patient-derived organoids and led to a significant increase in survival to tumor endpoint in xenograft models in vivo, compared to control or single-agent treatment (44).